Research and Markets: Commercial Insight: Antidepressants - Novel Mechanism Offers Hope In Depressed Market - Market to Decline at a Rate of -2.0% Between 2008 and 2018

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/881581/commercial_insight) has
announced the addition of the "Commercial Insight: Antidepressants - Novel
Mechanism Offers Hope in Depressed Market" report to their offering.

With current blockbuster brands facing generic competition, Datamonitor
forecasts the antidepressant market to decline at a compound annual growth rate
of -2.0% between 2008 and 2018. However, an antidepressant with a novel
mechanism of action has huge commercial potential and the most promising
candidate to date is Servier and Novartis's melatonin agonist and serotonin
antagonist Valdoxan (agomelatine).

Scope

* In-depth analysis of the current and future antidepressant drug class market
across the US, Japan, France, Germany, Italy, Spain and the UK.
* Country-specific total brand sales forecasts for key products, generics and
pipeline agents across the seven major markets to 2018.
* Assessment and appreciation of the numerous opportunities and threats present
in the antidepressant market, with analysis of emerging markets trends.
* Case study evaluation of the strategies employed by key players in the
antidepressant drug class market, including Wyeth, Forest, and Lundbeck.

Highlights of this title

Japan will remain a key growth market for antidepressant sales, shown through
the launch of Remeron (mirtazapine; Schering Plough), Lexapro (escitalopram;
Lundbeck and Mochida), Cymbalta (duloxetine; Eli Lilly and Shionogi) and Pristiq
(desvenlafaxine; Wyeth).

Eli Lilly's efforts to gain a broad range of indication approvals for Cymbalta
has been a key differentiator from Effexor (venlafaxine, Wyeth). The approvals
for diabetic peripheral neuropathic pain (US and EU) and fibromyalgia (US only)
will help drive Cymbalta's uptake through the forecast period, before the entry
of generic duloxetine in 2012.

With its innovative mode of action, strong efficacy and favorable side-effect
profile, Valdoxan (agomelatine; Servier and Novartis) is an exciting new
antidepressant. Assuming US launch in 2012 (EU launch came in 2009), Datamonitor
expects Valdoxan to prosper due to the lack of other truly novel pipeline
products over the 10-year forecast period.

Key reasons to purchase this title

* Quantify the current and future size of the antidepressant drug class market.
* Assess the impact of recent and anticipated events (patent expiries and new
product launches) on the antidepressant drug class market.
* Understand the country-specific impact of key events in the antidepressant
drug class market during the forecast period 2009 to 2018.

Key Topics Covered:

* CHAPTER 1 EXECUTIVE SUMMARY
* CHAPTER 2 MARKET DEFINITION
* CHAPTER 3 MARKET OVERVIEW
* CHAPTER 4 BRAND DYNAMICS
* CHAPTER 5 KEY DEVELOPERS
* CHAPTER 6 CASE STUDIES
* BIBLIOGRAPHY
* List of Tables

For more information visit
http://www.researchandmarkets.com/research/881581/commercial_insight

Source: Datamonitor

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Copyright Business Wire 2009